Quarterly report pursuant to Section 13 or 15(d)

12. Stock-based Compensation

v3.19.2
12. Stock-based Compensation
9 Months Ended
Jun. 30, 2019
Share-based Payment Arrangement, Noncash Expense [Abstract]  
Stock-based Compensation

Note 12:        Stock-Based Compensation

 

From time to time, the Company grants stock options and restricted stock awards to directors, officers and employees. These awards are valued at the grant date by determining the fair value of the instruments, net of estimated forfeitures. The value of each award is amortized on a straight-line basis over the requisite service period.

 

Stock Options

 

The following table summarizes stock option activity for the twelve months ended September 30, 2018 and the nine months ended June 30, 2019:

 

          Weighted     Weighted        
          Average     Average        
    Number of     Exercise     Remaining        
    Shares     Price     Contractual Life     Intrinsic Value  
Outstanding at September 30, 2017     211,668     $ 13.19       3.47     $ 454,417  
Granted     20,000       32.24       9.02          
Exercised                              
Forfeited                              
Outstanding at September 30, 2018     231,668     $ 14.84       3.04     $ 162,500  
Exercisable at September 30, 2018     190,639     $ 11.89       2.08     $ 162,500  
                                 
                                 
Outstanding at September 30, 2018     231,668     $ 14.84       3.04     $ 162,500  
Granted                              
Exercised                              
Forfeited     (31,250 )                        
Outstanding at June 30, 2019     200,418     $ 15.88       2.63     $  
Exercisable at June 30, 2019     169,820     $ 13.65       1.64     $  

 

The Company recognized compensation expense of $31,602 and $49,817 during the three months ended June 30, 2019 and 2018, respectively, related to stock option awards granted to certain employees and officers based on the grant date fair value of the awards, net of estimated forfeitures. The Company recognized compensation expense of $109,803 and $447,970 during the nine months ended June 30, 2019 and 2018, respectively.

 

At June 30, 2019, the Company has $177,002 of unrecognized compensation expense (net of estimated forfeitures) associated with stock option awards which the company expects to recognize as compensation expense through October of 2022.

 

The exercise price for stock options outstanding and exercisable outstanding at June 30, 2019 is as follows:

 

Outstanding     Exercisable  
Number of     Exercise     Number of     Exercise  
Options     Price     Options     Price  
  25,000       7.50       25,000       7.50  
  31,250       10.00       31,250       10.00  
  4,167       10.86       4,167       10.86  
  4,167       10.86       4,167       10.86  
  4,167       10.86       2,430       10.86  
  4,167       10.86                  
  6,250       12.50       6,250       12.50  
  6,250       15.00       6,250       15.00  
  75,000       15.18       75,000       15.18  
  8,000       23.41       8,000       23.41  
  8,000       27.60       8,000       27.60  
  8,000       31.74                  
  8,000       36.50                  
  8,000       41.98                  
  200,418               170,514          

 

The following table summarizes information about the Company’s non-vested shares outstanding as of June 30, 2019 and September 30, 2018:

 

          Average  
    Number of     Grant-Date  
Non-vested Shares   Shares     Fair Value  
Non-vested at September 30, 2017     36,668     $ 17.70  
Granted     20,000     $ 10.14  
Vested     (15,639 )   $ 15.72  
Non-vested at September 30, 2018     41,029     $ 12.88  
                 
Non-vested at September 30, 2018     41,029     $ 12.88  
Granted         $  
Vested     (11,125 )   $ 13.88  
Non-vested at June 30, 2019     29,904     $ 14.14  

 

Options were granted during fiscal 2018, where the exercise price was less than the common stock price at the date of grant or where the exercise price was greater than the common stock price at the date of grant. There have been no options granted in fiscal 2019 through June 30, 2019. The assumptions used in calculating the fair value of stock options granted in fiscal 2018 use the Black-Scholes option pricing model for options granted were as follows:

 

Risk-free interest rate 1.25%
Expected life of the options 5 and 10 years
Expected volatility 107%
Expected dividend yield 0%